SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study.

ABSTRACT:

Background

The identification of high-risk population patients is key to the personalized treatment options for the stage II colorectal cancers. The use of proteomics in the prognosis of patients with stage II colorectal cancer remains unclear.

Methods

Using quantitative proteomics, we analyzed proteins that are differentially expressed in the tumor and adjacent normal tissues of 11 paired colorectal cancer patients with and without recurrence selected by a nested case-control design. Of the 21 identified proteins, we selected one candidate protein. The association of the corresponding gene of the selected protein with overall survival (OS) and adjuvant chemotherapy was analyzed using two independent cohorts of patients with stages II colorectal cancer.

Results

Steril

SUBMITTER: You D 

PROVIDER: S-EPMC9376296 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature